These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 33693750)
1. Gag p24 Is a Marker of Human Immunodeficiency Virus Expression in Tissues and Correlates With Immune Response. Wu G; Zuck P; Goh SL; Milush JM; Vohra P; Wong JK; Somsouk M; Yukl SA; Shacklett BL; Chomont N; Haase AT; Hatano H; Schacker TW; Deeks SG; Hazuda DJ; Hunt PW; Howell BJ J Infect Dis; 2021 Nov; 224(9):1593-1598. PubMed ID: 33693750 [TBL] [Abstract][Full Text] [Related]
2. Poor HIV control in HLA-B*27 and B*57/58 noncontrollers is associated with limited number of polyfunctional Gag p24-specific CD8+ T cells. Techakriengkrai N; Tansiri Y; Hansasuta P AIDS; 2013 Jan; 27(1):17-27. PubMed ID: 23079801 [TBL] [Abstract][Full Text] [Related]
3. Polyfunctional CD4(+) T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine. Van Braeckel E; Desombere I; Clement F; Vandekerckhove L; Verhofstede C; Vogelaers D; Leroux-Roels G Vaccine; 2013 Aug; 31(36):3739-46. PubMed ID: 23707169 [TBL] [Abstract][Full Text] [Related]
4. Combined Env- and Gag-specific T cell responses in relation to programmed death-1 receptor and CD4 T cell loss rates in human immunodeficiency virus-1 infection. Pettersen FO; Taskén K; Kvale D Clin Exp Immunol; 2010 Aug; 161(2):315-23. PubMed ID: 20491784 [TBL] [Abstract][Full Text] [Related]
5. Development of a Live Recombinant BCG Expressing Human Immunodeficiency Virus Type 1 (HIV-1) Gag Using a pMyong2 Vector System: Potential Use As a Novel HIV-1 Vaccine. Kim BJ; Kim BR; Kook YH; Kim BJ Front Immunol; 2018; 9():643. PubMed ID: 29636755 [TBL] [Abstract][Full Text] [Related]
7. Human immunodeficiency virus type 1 (HIV-1)-specific CD4+ T cells that proliferate in vitro detected in samples from most viremic subjects and inversely associated with plasma HIV-1 levels. Boritz E; Palmer BE; Wilson CC J Virol; 2004 Nov; 78(22):12638-46. PubMed ID: 15507650 [TBL] [Abstract][Full Text] [Related]
8. Human Immunodeficiency Virus Persistence and T-Cell Activation in Blood, Rectal, and Lymph Node Tissue in Human Immunodeficiency Virus-Infected Individuals Receiving Suppressive Antiretroviral Therapy. Khoury G; Fromentin R; Solomon A; Hartogensis W; Killian M; Hoh R; Somsouk M; Hunt PW; Girling V; Sinclair E; Bacchetti P; Anderson JL; Hecht FM; Deeks SG; Cameron PU; Chomont N; Lewin SR J Infect Dis; 2017 Mar; 215(6):911-919. PubMed ID: 28453847 [TBL] [Abstract][Full Text] [Related]
9. Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection. Boaz MJ; Waters A; Murad S; Easterbrook PJ; Vyakarnam A J Immunol; 2002 Dec; 169(11):6376-85. PubMed ID: 12444145 [TBL] [Abstract][Full Text] [Related]
10. HIV-1-specific CD4+ T-cell responses are not associated with significant viral epitope variation in persons with persistent plasma viremia. Koeppe JR; Campbell TB; Rapaport EL; Wilson CC J Acquir Immune Defic Syndr; 2006 Feb; 41(2):140-8. PubMed ID: 16394844 [TBL] [Abstract][Full Text] [Related]
11. The affinity of IgG antibodies to gag p24 and p17 in HIV-1-infected patients correlates with disease progression. Chargelegue D; Stanley CM; O'Toole CM; Colvin BT; Steward MW Clin Exp Immunol; 1995 Feb; 99(2):175-81. PubMed ID: 7851008 [TBL] [Abstract][Full Text] [Related]
12. Mechanisms of HIV non-progression; robust and sustained CD4+ T-cell proliferative responses to p24 antigen correlate with control of viraemia and lack of disease progression after long-term transfusion-acquired HIV-1 infection. Dyer WB; Zaunders JJ; Yuan FF; Wang B; Learmont JC; Geczy AF; Saksena NK; McPhee DA; Gorry PR; Sullivan JS Retrovirology; 2008 Dec; 5():112. PubMed ID: 19077215 [TBL] [Abstract][Full Text] [Related]
13. Evidence for Gag p24-specific CD4 T cells with reduced susceptibility to R5 HIV-1 infection in a UK cohort of HIV-exposed-seronegative subjects. Eyeson J; King D; Boaz MJ; Sefia E; Tomkins S; Waters A; Easterbrook PJ; Vyakarnam A AIDS; 2003 Nov; 17(16):2299-311. PubMed ID: 14571181 [TBL] [Abstract][Full Text] [Related]
14. CD4+ T cell targeting of human immunodeficiency virus type 1 (HIV-1) peptide sequences present in vivo during chronic, progressive HIV-1 disease. Boritz E; Rapaport EL; Campbell TB; Koeppe JR; Wilson CC Virology; 2007 Apr; 361(1):34-44. PubMed ID: 17169395 [TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression. Lindenburg CE; Stolte I; Langendam MW; Miedema F; Williams IG; Colebunders R; Weber JN; Fisher M; Coutinho RA Vaccine; 2002 May; 20(17-18):2343-7. PubMed ID: 12009290 [TBL] [Abstract][Full Text] [Related]
16. Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T cell responses. Ondondo BO; Yang H; Dong T; di Gleria K; Suttill A; Conlon C; Brown D; Williams P; Rowland-Jones SL; Hanke T; McMichael AJ; Dorrell L Eur J Immunol; 2006 Oct; 36(10):2585-94. PubMed ID: 17013989 [TBL] [Abstract][Full Text] [Related]
17. Association between HIV Type 1-specific T cell responses and CD4+ T cell counts or CD4+:CD8+ T cell ratios in HIV Type 1 subtype B infection in China. Wang S; Zhuang Y; Zhai S; Zhao S; Kang W; Li X; Yu XG; Walker BD; Altfeld MA; Sun Y AIDS Res Hum Retroviruses; 2006 Aug; 22(8):780-7. PubMed ID: 16910834 [TBL] [Abstract][Full Text] [Related]